ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $37M | $-21M | $-26M | $-24M | -91.1% | 17.8% | - |
| 2024 | $31M | $-16M | $-19M | $-9M | -74.5% | 31.0% | - |
| 2023 | $24M | $-21M | $-22M | $-15M | -104.3% | 16.6% | - |
| 2022 | $21M | $-16M | $-16M | $-17M | -44.6% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 20.55 | 23.95 | 31.39 | 36.97 |
| Cost Of Revenue | 7.02 | 10.34 | 12.27 | 14.28 |
| Gross Profit | 13.53 | 13.61 | 19.12 | 22.69 |
| Operating Expense | 29.86 | 36.06 | 38.86 | 46.86 |
| Operating Income | -16.33 | -22.45 | -19.73 | -24.16 |
| EBITDA | -15.58 | -20.99 | -16.48 | -20.86 |
| EBIT | -16.35 | -22.45 | -18.38 | -23.10 |
| Pretax Income | -16.43 | -22.09 | -18.90 | -25.48 |
| Tax Provision | 0 | 0 | 0.01 | 0.06 |
| Net Income | -16.43 | -22.09 | -18.91 | -25.54 |
| Net Income Common Stockholders | -16.43 | -22.09 | -18.91 | -25.54 |
| Total Expenses | 36.88 | 46.40 | 51.12 | 61.13 |
| Interest Expense | 0.08 | 0 | 0.52 | 2.39 |
| Interest Income | 0 | 0.39 | 1.39 | 1.21 |
| Research And Development | 10.89 | 11.71 | 12.39 | 13.90 |
| Selling General And Administration | 18.97 | 24.35 | 26.46 | 32.96 |
| Normalized EBITDA | -15.58 | -20.99 | -16.48 | -20.86 |
| Normalized Income | -16.43 | -22.09 | -18.91 | -25.54 |
| Basic EPS | -0.68 | -0.90 | -0.70 | 0 |
| Diluted EPS | -0.68 | -0.90 | -0.70 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0.21 | 0.21 |
| Net Income From Continuing Operation Net Minority Interest | -16.43 | -22.09 | -18.91 | -25.54 |
| Reconciled Depreciation | 0.78 | 1.46 | 1.90 | 2.24 |
| Reconciled Cost Of Revenue | 7.02 | 10.34 | 12.27 | 14.28 |
| Net Interest Income | -0.08 | 0.39 | 0.87 | -1.18 |
| Net Income From Continuing And Discontinued Operation | -16.43 | -22.09 | -18.91 | -25.54 |
| Total Operating Income As Reported | -16.33 | -22.45 | -19.73 | -24.16 |
| Diluted Average Shares | 24.18 | 24.61 | 27.03 | 0 |
| Basic Average Shares | 24.18 | 24.61 | 27.03 | 0 |
| Diluted NI Availto Com Stockholders | -16.43 | -22.09 | -18.91 | -25.54 |
| Net Income Including Noncontrolling Interests | -16.43 | -22.09 | -18.91 | -25.54 |
| Net Income Continuous Operations | -16.43 | -22.09 | -18.91 | -25.54 |
| Other Income Expense | -0.02 | -0.03 | -0.04 | -0.15 |
| Other Non Operating Income Expenses | -0.02 | -0.03 | -0.04 | -0.15 |
| Net Non Operating Interest Income Expense | -0.08 | 0.39 | 0.87 | -1.18 |
| Interest Expense Non Operating | 0.08 | 0 | 0.52 | 2.39 |
| Interest Income Non Operating | 0 | 0.39 | 1.39 | 1.21 |
| Selling And Marketing Expense | 9.36 | 12.60 | 14.48 | 16.46 |
| General And Administrative Expense | 9.61 | 11.76 | 11.99 | 16.50 |
| Other Gand A | 9.61 | 11.76 | 11.99 | 16.50 |
| Operating Revenue | 20.55 | 23.95 | 31.39 | 36.97 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| ClearPoint Neuro, Inc.this co. | CLPT | $310M | - | 10.84 | -91.1% | -14.85 |
| SIGA Technologies, Inc. | SIGA | $325M | 14.16 | 1.63 | 11.7% | 7.02 |
| DiaMedica Therapeutics Inc. | DMAC | $321M | - | 5.71 | -58.4% | -7.61 |
| CapsoVision, Inc. | CV | $319M | - | 22.61 | -190.9% | -12.32 |
| Anavex Life Sciences Corp. | AVXL | $302M |
| - |
| 2.39 |
| -48.9% |
| - |
| Compass Therapeutics, Inc. | CMPX | $301M | - | 1.51 | -33.8% | -1.40 |
| Greenwich LifeSciences, Inc. | GLSI | $299M | - | 136.71 | -623.1% | -15.09 |
| Rezolute, Inc. | RZLT | $299M | - | 2.53 | -45.9% | -1.89 |
| Organogenesis Holdings Inc. | ORGO | $296M | 15.33 | 0.97 | 8.5% | 5.55 |
| Peer Median | - | 14.74 | 2.46 | -47.4% | -1.89 | |